IL156777A0 - Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists - Google Patents

Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Info

Publication number
IL156777A0
IL156777A0 IL15677702A IL15677702A IL156777A0 IL 156777 A0 IL156777 A0 IL 156777A0 IL 15677702 A IL15677702 A IL 15677702A IL 15677702 A IL15677702 A IL 15677702A IL 156777 A0 IL156777 A0 IL 156777A0
Authority
IL
Israel
Prior art keywords
dementia
treatment
neurodegenerative diseases
lhrh antagonists
intermediate doses
Prior art date
Application number
IL15677702A
Other languages
English (en)
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of IL156777A0 publication Critical patent/IL156777A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL15677702A 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists IL156777A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28743401P 2001-04-30 2001-04-30
PCT/EP2002/004677 WO2002102401A1 (en) 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Publications (1)

Publication Number Publication Date
IL156777A0 true IL156777A0 (en) 2004-02-08

Family

ID=23102886

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15677702A IL156777A0 (en) 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Country Status (27)

Country Link
US (1) US7288517B2 (OSRAM)
EP (1) EP1392348B1 (OSRAM)
JP (1) JP2004529207A (OSRAM)
KR (1) KR20040000446A (OSRAM)
CN (1) CN1317030C (OSRAM)
AT (1) ATE400287T1 (OSRAM)
AU (1) AU2002310788B2 (OSRAM)
BG (1) BG108339A (OSRAM)
BR (1) BR0209290A (OSRAM)
CA (1) CA2444876A1 (OSRAM)
CZ (1) CZ20033167A3 (OSRAM)
DE (1) DE60227507D1 (OSRAM)
DK (1) DK1392348T3 (OSRAM)
ES (1) ES2307760T3 (OSRAM)
HU (1) HUP0400067A2 (OSRAM)
IL (1) IL156777A0 (OSRAM)
MX (1) MXPA03008666A (OSRAM)
NO (1) NO20034322D0 (OSRAM)
NZ (1) NZ544417A (OSRAM)
PL (1) PL362319A1 (OSRAM)
PT (1) PT1392348E (OSRAM)
RU (1) RU2319501C2 (OSRAM)
SI (1) SI1392348T1 (OSRAM)
SK (1) SK14512003A3 (OSRAM)
UA (1) UA80679C2 (OSRAM)
WO (1) WO2002102401A1 (OSRAM)
ZA (1) ZA200305326B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
CN1186326C (zh) 2000-07-05 2005-01-26 山之内制药株式会社 丙－1,3－二酮衍生物
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
WO2005118556A1 (ja) * 2004-06-04 2005-12-15 Astellas Pharma Inc. プロパン－１，３－ジオン誘導体又はその塩
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
CN101087618A (zh) * 2004-12-23 2007-12-12 航行药物公司 醋酸亮丙瑞林和乙酰胆碱酯酶抑制剂或nmda受体抑制剂在阿尔茨海默氏病治疗中的应用
SI1864976T1 (sl) 2005-03-31 2012-12-31 Astellas Pharma Inc. Propan-1,3-dionski derivat ali njegova sol
WO2008046919A2 (en) * 2006-10-21 2008-04-24 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
CA2699100A1 (en) * 2007-09-11 2009-04-02 Dorian Bevec Use of a peptide as a therapeutic agent
WO2009033765A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
WO2012041814A1 (en) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
WO2025155903A1 (en) * 2024-01-19 2025-07-24 Temple University-Of The Commonwealth System Of Higher Education Compositions of antioxidant translation modulators for treating neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
AU710926B2 (en) * 1996-05-20 1999-09-30 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
AU767440B2 (en) * 1999-05-14 2003-11-13 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo(1,2-A)pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
CA2309395A1 (en) 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
JP2003512379A (ja) * 1999-10-15 2003-04-02 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストおよびそれに関連する方法
CA2406832A1 (en) 2000-04-13 2002-10-10 Takeda Chemical Industries, Ltd. Preventives/remedies for alzheimer's disease
CN1186326C (zh) * 2000-07-05 2005-01-26 山之内制药株式会社 丙－1,3－二酮衍生物

Also Published As

Publication number Publication date
UA80679C2 (en) 2007-10-25
NZ544417A (en) 2008-03-28
ATE400287T1 (de) 2008-07-15
PL362319A1 (en) 2004-10-18
ES2307760T3 (es) 2008-12-01
CA2444876A1 (en) 2002-12-27
US20020177556A1 (en) 2002-11-28
HK1072000A1 (en) 2005-08-12
DE60227507D1 (de) 2008-08-21
JP2004529207A (ja) 2004-09-24
SI1392348T1 (sl) 2008-12-31
NO20034322L (no) 2003-09-26
US7288517B2 (en) 2007-10-30
ZA200305326B (en) 2003-07-30
BG108339A (bg) 2004-11-30
CN1317030C (zh) 2007-05-23
CN1575185A (zh) 2005-02-02
NO20034322D0 (no) 2003-09-26
EP1392348A1 (en) 2004-03-03
EP1392348B1 (en) 2008-07-09
RU2003134949A (ru) 2005-02-10
DK1392348T3 (da) 2008-09-29
KR20040000446A (ko) 2004-01-03
MXPA03008666A (es) 2004-10-15
CZ20033167A3 (cs) 2004-08-18
WO2002102401A1 (en) 2002-12-27
SK14512003A3 (sk) 2004-08-03
BR0209290A (pt) 2004-07-13
RU2319501C2 (ru) 2008-03-20
AU2002310788B2 (en) 2007-04-05
PT1392348E (pt) 2008-09-09
HUP0400067A2 (hu) 2004-04-28

Similar Documents

Publication Publication Date Title
IL156777A0 (en) Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists
LU92854I2 (fr) Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil
MY134906A (en) Prevention and treatment of amyloidogenic disease
MY136707A (en) Thrombopoietin mimetics
GB0223040D0 (en) Therapeutic compounds
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
JO2207B1 (en) Pharmaceutical radiological compounds to diagnose Alzheimer's disease
EA200400352A1 (ru) Органолептически приемлемые распадающиеся во рту композиции
MY124786A (en) Bis-arylsulfones
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
WO2003053136A3 (en) Triple transgenic mouse model of alzheimer's disease
BG105651A (en) Vitronectin receptor antagonist
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
MXPA03011502A (es) Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
WO2002062383A3 (en) Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases
MXPA04000870A (es) Uso de antagonistas-lhrh para mejorar la inmunidad mediada por celula-t.
PL377110A1 (pl) Zapobieganie i leczenie choroby Alzheimera
MXPA03008406A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina.
AU2002312797A1 (en) Peptide for the diagnosis and therapy of alzheimer's disease
HK1063639A (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
AU2002319451A1 (en) Therapeutic strategies for prevention and treatment of alzheimer's disease
YU9099A (en) Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one for producting a pharmaceutical preparation for treatment of the alzheimer's disease